Epigenetic modifier m⁶A methylation: insights into the pathogenesis and therapeutic potential of autoimmune diseases

作者：Xue Lv, Wenxin Zhang, Yuefang Liu, Yuelin Hu, Xin Wang, Hongsong Yu · 发表于：Journal of Translational Medicine · 年份：2025 · DOI：10.1186/s12967-025-07347-9 · 被引用次数：3 · 研究领域：RNA modifications and cancer、interferon and immune responses、Cancer-related gene regulation

N6-methyladenosine (m⁶A) methylation is a predominant form of RNA modification in eukaryotic cells. It exerts profound influence over the processing of mRNA, rRNA and tRNA, thereby playing a critical role in various biological processes, including RNA transcription, splicing, degradation, and translation regulation. The m⁶A methylation significantly affects cell fate and signal transduction pathways by regulating gene expression. Notably, aberrant m⁶A modification is strongly associated with the onset and progression of autoimmune diseases. Emerging evidence indicates that these regulatory factors display disease-specific expression patterns and functional roles, influencing immune-cell differentiation and effector functions, inflammatory responses, and tissue injury. This article provides an overview of recent advances in m⁶A biology in autoimmunity and discusses their implications for diagnosis and therapeutic intervention.Clinical trial number Not applicable.